Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma is a research paper published in JAMA Network Open (2024). On theSindex it has a DataRank of 0.864. It has been cited 21 times, with 18 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.464
From this paper's citation signal
Citation Network Contribution
0.400
From 11 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 18 citers.
NCI NIH HHS
Grant: UG1 CA189828
NCI NIH HHS
Grant: UG1 CA232760
NCI NIH HHS
Grant: U01 CA233169
NCI NIH HHS
Grant: UG1 CA233160
NCI NIH HHS
Grant: P50 CA186781
NCI NIH HHS
Grant: UG1 CA189956
National Institutes of Health
Grant: 1UG1CA189956-01
Wisconsin NCI Community Oncology Research Program (WiNCORP)
National Institutes of Health
Grant: 5UG1CA233160-03
UM LAPs - UG1 Grant
National Institutes of Health
Grant: 3UG1CA232760-06S1
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)
National Institutes of Health
Grant: 3U01CA233169-05S1
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
FWCI
6.09
Citation Percentile
1.0%
Influential Citations
1
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals